Advanced Search

 

Study ID Status Title Patient Level Data
104730 Completed A phase III, multicentre booster vaccination study to assess the immunogenicity, safety and reactogenicity of a dose of Mencevax™ ACWY at 24 to 30 months of age in subjects primed with an investigational vaccination regimen in study 100480 and boosted at 15 to 24 months of age in study 104727. Study Listed on ClinicalStudyDataRequest.com
104731 Completed Multicenter, Phase II Dosimetry/Validation Study of 131Iodine–Anti B1 (Murine) Radioimmunotherapy for Chemotherapy Refractory Low Grade B Cell Lymphomas and Low Grade Lymphomas that Have Transformed to Higher Grade Histologies Study Listed on ClinicalStudyDataRequest.com
104733 Completed Demonstrate lot-to-lot consistency of final production method of GSK Biologicals' Hib-MenAC vaccine mixed extemporaneously with Tritanrix™-HepB & demonstrate its non-inferiority vs Tritanrix™-HepB/Hiberix™ in healthy infants at 2, 4 and 6 months Study Listed on ClinicalStudyDataRequest.com
104743 Completed A Phase IIb randomized, double-blind, controlled study of the safety, immunogenicity and proof-of-concept of RTS,S/AS02A, and RTS,S/AS01B, two candidate malaria vaccines in malaria-experienced adults living in Western Kenya.
104745 Completed Phase III Vaccination Study for Evaluation of Immunogenicity and Reactogenicity of Influsplit SSW 2004/2005 in People age 18 or beyond Study Listed on ClinicalStudyDataRequest.com
104756 Completed Booster Vaccination Study to Assess Safety & Reactogenicity of a Dose of DTPw-HBV/Hib Vaccine and to Assess the Immunogenicity, Safety & Reactogenicity of a Dose of Mencevax™ ACW in Subjects Primed in Study 759346/007 Study Listed on ClinicalStudyDataRequest.com
104772 Completed Assess lot-to-lot consistency of GSK Biologicals' HPV-16/18 L1/AS04 vaccine following manufacturing adjustments administered intramuscularly according to a 0,1,6-mth schedule in healthy female subjects (18-25 y) Study Listed on ClinicalStudyDataRequest.com
104774 Completed Microalbuminuria as a Predictor of the Development of Kidney Disease in HIV-Positive Patients
104798 Completed A phase II study to assess the efficacy, immunogenicity and safety of GSK Biologicals' HPV-16/18 L1 VLP AS04 (Cervarix TM) vaccine administered intramuscularly according to a 0, 1, 6 month schedule in healthy Japanese female subjects aged 20 - 25 years. Study Listed on ClinicalStudyDataRequest.com
104807 Completed Post-Marketing Clinical Study of EPZICOM Tablet (Lamivudine / Abacavir Sulfate) – Pharmacokinetic Study in HIV-Infected Patients –
104820 Completed A study to evaluate safety, immunogenicity and efficacy of GSK Biologicals HPV-16/18 L1/AS04 vaccine administered intramuscularly according to a three-dose schedule (0, 1, 6 month) in healthy adult female subjects aged 26 years and above Study Listed on ClinicalStudyDataRequest.com
104851 Completed Prospective, Randomized, Controlled Assessment of Once-Daily Controlled Release COREG CR versus Twice Daily COREG Immediate Release (IR) On Measures of Compliance and Quality of Life in Patients with Heart Failure and Left Ventricular Systolic Dysfunction
104858 Completed A phase III, single-blind, randomized study to evaluate the immunogenicity and safety of Fluarix® (GSK Biologicals') compared with Fluzone® (Aventis Pasteur/Sanofi) administered intramuscularly in children (6 months and older) Study Listed on ClinicalStudyDataRequest.com
104864/005 Completed Phase I study of topotecan
104864/010 Completed An Open Phase I Study to Determine the Maximal Tolerated Dose of Topotecan HCl Administered Intravenously as a Single Dose Every 21 Days in Patients with Solid Tumors Refractory to All Known Forms of Effective Therapy
104864/012 Completed An Open Phase II Study To Evaluate The Efficacy And Toxicity Of Topotecan Administered Intravenously As Five Daily Infusions Every 21 Days To Women With Advanced Epithelial Ovarian Carcinoma
104864/014 Completed A phase II trial with topotecan 1.5 mg/m2/day for five consecutive days every 21 days in sensitive and refractory subjects with small cell lung cancer (SCLC).
104864/015 Completed An Open Phase II Study to Evaluate the Efficacy and Toxicity of Topotecan Administered Intravenously as Five Daily Infusions Every 21 Days to Patients with Advanced Non-Small Cell Lung Cancer.
104864/017 Completed A Phase I Study of Topotecan HCl Administered on a Daily Times Five Schedule with a Single Infusion of Cisplatin every Three Weeks to Patients with Advanced Non-small Cell Lung Carcinoma.
104864/032 Completed An open label evaluation of topotecan administered intravenously as five daily 30 minute infusions every 21 days to patients with ovarian tumours refractory to other therapies
104864/033 Completed An open, multicenter, Phase II study of intravenous topotecan, given as five daily doses every 21 days, in advanced epithelial ovarian cancer to patients who have failed prior chemotherapy containing paclitaxel and cisplatin or carboplatin
104864/034 Completed An open, multicentre, Phase II study of intravenous topotecan, given as 5 daily doses every 21 days, in advanced epithelial ovarian cancer
104864/039 Completed An Open-Label, Multicenter, Randomized, Phase III Study of Topotecan HCl as Single Agent, Second-Line Therapy (Administered Intravenously as Five Daily Doses Every 21 Days) Versus Taxol. (Administered as a Three-Hour Infusion Every 21 Days) in Women With Advanced Epithelial Ovarian Carcinoma
104864/047 Completed Single-dose Oral Bioavailability and Pharmacokinetics of Topotecan
104864/048 Completed A phase I study to determine the effect of food co-administration on the pharmacokinetics of oral topotecan and to determine the absolute bioavailability of oral topotecan in subjects with malignant solid tumours

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.